Novo-Nordisk A/S
NVO Real Time Price USDRecent trades of NVO by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in NVO holdings by institutional investors
Quarterly net insider trading by NVO's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$2,010,000 Oct 20, 2026 Issue: Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills) Health Issues Budget/Appropriations
-
$1,300,000 Jul 20, 2026 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$1,290,000 Apr 20, 2026 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$2,120,000 Jan 20, 2026 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$1,730,000 Oct 20, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$1,050,000 Jul 16, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$2,330,000 Apr 18, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark
-
$1,240,000 Jan 17, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark
-
$780,000 Oct 18, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$1,060,000 Jul 19, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$1,490,000 Apr 18, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$60,000 Feb 07, 2024 Issue: Budget/Appropriations Pharmacy Medicare/Medicaid Health Issues
-
$600,000 Oct 19, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
Former government officials who have lobbied for NVO
106 former government officials from 65 congressional offices at 21 lobbying firms have lobbied for NVO, most recently Oct 20, 2026.
-
Christopher Wilcox House LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings -
Jeanne Haggerty Senate Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member -
Robert Butora Senate Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess -
Raissa Downs Senate Prin. Dep. Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Staff Dir., Sub. Cmte. on Employment, Sen. HELP Cmte.
-
Jennifer Young Congress Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Cmte. Staff, House Cmte. on Ways and Means; Cmte. Staff, Sen. Cmte. on Finance
-
Pamela Smith Senate Leg. Dir., Sen. Tom Harkin; Dep. Staff Dir., Senate HELP Cmte; Staff Dir., Senate HELP Cmte; Counselor to the Asst. AG, Civil Div., Dept of Justice; Spec Counsel, Ofc of Leg. Affairs, Dept of Justice; Counsel and LA, Senator Carol Moseley-Braun -
Emily Murry House Staff Dir., Sub. Cmte. on Health, W&M Cmte; Sr. Policy Advisor, Majority Leader McCarthy; Policy Advisor, Majority Whip McCarthy; Professional Staff, Republican Study Cmte.; Leg. Aid, Rep. Ken Calvert; Leg. Asst., Rep. Tom Price
-
Peter Fise Congress Health Counsel for Sen. Cmte on Finance, Health Counsel for Sen. Jeanne Shaheen, Staff Assistant for House Cmte on Oversight & Government Reform
NVO Estimated quarterly lobbying spending
NVO Revenue by Segment or Geography
New NVO patent grants
-
Patent Title: Antibodies that are capable of specifically binding tissue factor pathway inhibitor Jan. 05, 2016
-
Patent Title: Remodeling and glycopegylation of fibroblast growth factor (fgf) Dec. 01, 2015
-
Patent Title: Injection device with mode locking means Nov. 24, 2015
-
Patent Title: Low friction systems and devices Nov. 17, 2015
-
Patent Title: Human insulin analogues and derivatives comprising cysteine substitutions Nov. 17, 2015
-
Patent Title: Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants Nov. 17, 2015
-
Patent Title: Glycosylation of peptides via o-linked glycosylation sequences Nov. 17, 2015
-
Patent Title: Electronically assisted drug delivery device Nov. 17, 2015
-
Patent Title: Secure pairing of electronic devices using dual means of communication Nov. 03, 2015
-
Patent Title: Conjugated factor viii molecules Oct. 06, 2015
-
Patent Title: Insulin analogues with an acyl and alkylene glycol moiety Oct. 06, 2015
-
Patent Title: Magnetic time delay indicator and an injection device incorporating such Sep. 29, 2015
-
Patent Title: Shieldable needle assembly with biased safety shield Sep. 22, 2015
-
Patent Title: Dial-down mechanism for wind-up pen Sep. 15, 2015
-
Patent Title: Antibodies against human nkg2d and uses thereof Sep. 08, 2015
-
Patent Title: Compounds suitable for treatment of haemophilia Sep. 08, 2015
-
Patent Title: Back needle Sep. 08, 2015
-
Patent Title: Process for preparing fgf21 with low degree of o-glycosylation Sep. 01, 2015
-
Patent Title: Auto-priming injection device Aug. 25, 2015
-
Patent Title: Injection device with visual end-of-content indication Aug. 25, 2015
-
Patent Title: Medical device with value sensor Aug. 18, 2015
-
Patent Title: Automatic injection device with a top release mechanism Aug. 18, 2015
-
Patent Title: Electronic module for mechanical medication delivery devices Aug. 11, 2015
-
Patent Title: Dose setting mechanism for an injection device capable of presetting a maximum dose Aug. 11, 2015
-
Patent Title: Piston rod foot Aug. 11, 2015
-
Patent Title: Peptidyl α-hydroxyglycine α-amidating lyases Aug. 04, 2015
-
Patent Title: Disposable double point injection needle and an insulin injection system comprising a disposable double point injection needle Aug. 04, 2015
-
Patent Title: Medical assembly with monitoring device Jul. 28, 2015
-
Patent Title: Selective pyy compounds and uses thereof Jul. 21, 2015
-
Patent Title: Peptides derivatized with a-b-c-d- and their therapeutical use Jun. 30, 2015
-
Patent Title: Medical container protected against cracking Jun. 30, 2015
-
Patent Title: Therapeutic factor viii antibodies Jun. 23, 2015
-
Patent Title: Polypeptide protracting tags Jun. 23, 2015
-
Patent Title: Method for making mature insulin polypeptides Jun. 16, 2015
-
Patent Title: Medical delivery system with a rotatable coding element Jun. 09, 2015
-
Patent Title: Protease stabilized, acylated insulin analogues Jun. 02, 2015
-
Patent Title: Medical delivery device having air shot means Jun. 02, 2015
-
Patent Title: Long-acting gastrin derivatives May. 26, 2015
-
Patent Title: Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids May. 19, 2015
-
Patent Title: Pharmaceutical formulations comprising an insulin derivative May. 19, 2015
-
Patent Title: Glycopegylated granulocyte colony stimulating factor May. 12, 2015
-
Patent Title: Amylin analogues and pharmaceutical compositions thereof May. 12, 2015
-
Patent Title: Amylin analogs and pharmaceutical compositions thereof May. 05, 2015
-
Patent Title: Injection device May. 05, 2015
-
Patent Title: Conjugated fviii variants Apr. 28, 2015
-
Patent Title: Protease resistant insulin analogues Apr. 28, 2015
-
Patent Title: Medical injection device Apr. 28, 2015
-
Patent Title: Two-part hinged needle magazine Apr. 28, 2015
-
Patent Title: Acylated exendin-4 compounds Apr. 21, 2015
-
Patent Title: Determination of position of injection needle Apr. 14, 2015
Federal grants, loans, and purchases
Estimated quarterly amount awarded to NVO from public contracts
Recent insights relating to NVO
Pending bills that may affect NVO
|
Bill
|
Impact
|
Confidence
|
Date
|
|---|
Recent picks made for NVO stock on CNBC
ETFs with the largest estimated holdings in NVO
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $NVO stock a Buy, Sell, or Hold?
- What is the price target for $NVO stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $NVO stock?
- Who owns the most shares of $NVO stock?
- What funds own $NVO stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NVO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Novo-Nordisk A/S (NVO) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Novo-Nordisk A/S (NVO).
Quiver Premium charts NVO's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at NVO, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|